Evidence map›Paper›PMID 32948179›Full record

ArticleJournal of nanobiotechnology2020

Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo.

Jesse S Chen, Jingwen Chen, Somnath Bhattacharjee, Zhengyi Cao, Han Wang, Scott D Swanson, Hong Zong, James R Baker, Su He Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jesse S ChenDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Jingwen ChenDepartment of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Somnath BhattacharjeeDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Zhengyi CaoDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Han WangDepartment of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Scott D SwansonDepartment of Radiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Hong ZongDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
James R BakerDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.
Su He WangDepartment of Internal Medicine, Division of Allergy, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. shidasui@umich.edu.
University of Michigan–Ann Arbor · USShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted contrast nanoparticles for breast tumor imaging facilitates early detection and improves treatment efficacy of breast cancer. This manuscript reports the development of an epidermal growth factor receptor-2 (HER-2) specific, bi-modal, dendrimer conjugate to enhance computed tomography (CT) and magnetic resonance imaging (MRI) of HER-2-positive breast cancer. This material employs generation 5 poly(amidoamine) dendrimers, encapsulated gold nanoparticles, chelated gadolinium, and anti-human HER-2 antibody to produce the nanoparticle contrast agent.

resultsTesting in two mouse tumor models confirms this contrast agent's ability to image HER-2 positive tumors. Intravenous injection of this nanoparticle in mice bearing HER-2 positive mammary tumors significantly enhances MRI signal intensity by ~ 20% and improves CT resolution and contrast by two-fold. Results by flow cytometry and confocal microscopy validate the specific targeting of the conjugate and its internalization in human HER-2 positive cells.

conclusionThese results demonstrate that this nanoparticle conjugate can efficiently target and image HER-2 positive tumors in vivo and provide a basis for the development of this diagnostic tool for early detection, metastatic assessment and therapeutic monitoring of HER-2 positive cancers.

Indexed as

A549 CellsAnimalsAntibodiesBreast NeoplasmsDrug Delivery SystemsErb-b2 Receptor Tyrosine KinasesGadoliniumHumansKineticsMagnetic Resonance ImagingMiceMice, Inbred BALB CMice, Inbred C57BLMice, NudeMice, TransgenicNanoparticlesAntibodiesERBB2 protein, humanErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesGadoliniumBi-modal imagingComputerized tomographyHER-2Magnetic resonance imagingNanoparticlesTargeting

Identifiers

PMID32948179
PMCPMC7501678
OpenAlexW3087367572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.